Fundraising Fox
Scionxbio
Founded 2026 · 17 employees on LinkedIn · 1 known investors
Find your way into Scionxbio
Sign up to find every way you can get introduced to Scionxbio
- Your email: who you already know at Scionxbio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Scionxbio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
ScionX develops xRNA, an engineered RNA platform that uses site-specific chemical modifications and expanded non-natural building blocks to extend protein expression from days to months and deliver multiple coordinated payloads against several disease drivers. It applies a deep-learning design engine and combinatorial chemical synthesis to build long-acting RNA therapeutics, initially focused on cardiometabolic and other chronic diseases.
Investors · 1
Frequently asked questions
- What does Scionxbio do?
- ScionX develops xRNA, an engineered RNA platform that uses site-specific chemical modifications and expanded non-natural building blocks to extend protein expression from days to months and deliver multiple coordinated payloads against several disease drivers. It applies a deep-learning design engine and combinatorial chemical synthesis to build long-acting RNA therapeutics, initially focused on cardiometabolic and other chronic diseases.
- Who are Scionxbio's investors?
- Scionxbio's investors include Kindred Capital.